Antibiotic Therapy for Pseudomonas aeruginosa Bloodstream Infections: How Long Is Long Enough?

Clin Infect Dis. 2019 Nov 13;69(11):2011-2014. doi: 10.1093/cid/ciz223.

Abstract

In a multicenter, observational, propensity-score-weighted cohort of 249 adults with uncomplicated Pseudomonas aeruginosa bacteremia, patients receiving short-course (median, 9 days; interquartile range [IQR], 8-10) therapy had a similar odds of recurrent infection or death within 30 days as those receiving longer courses (median, 16 days; IQR, 14-17).

Keywords: Pseudomonas aeruginosa; cefepime; gram-negative bacteremia; piperacillin-tazobactam; treatment duration.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Bacteremia / drug therapy*
  • Bacteremia / microbiology*
  • Cefepime / therapeutic use
  • Female
  • Humans
  • Male
  • Middle Aged
  • Piperacillin, Tazobactam Drug Combination / therapeutic use*
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / pathogenicity*

Substances

  • Piperacillin, Tazobactam Drug Combination
  • Cefepime